Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Rituximab in Untreated Mantle Cell Lymphoma
NCT05004064Phase 2Active, not recruiting
- Sponsor
- University College London
- Start
- Nov 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by University College London. Started Nov 2023; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05004064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004064.